Appropriate trophoblast invasion into the maternal endometrium is essential for successful human implantation and placentation. Connective tissue growth factor (CTGF), also known as CCN2, is a matricellular protein that is expressed in the placenta. Interestingly, the CTGF expression levels in the placenta and serum from patients with severe preeclampsia or fetal growth restriction are higher than those from healthy controls. However, to date, the role of CTGF in the regulation of trophoblast cell invasion remains unclear. Transforming growth factor-b1 (TGF-b1) is a potent stimulator of CTGF expression and has been shown to inhibit trophoblast cell invasiveness. However, whether CTGF mediates TGF-b1-inhibited human trophoblast cell invasion is unknown. In the present study, we show that treatment with TGF-b1 upregulates CTGF expression in a human trophoblast cell line, HTR-8/SVneo, and in primary human trophoblast cells. Our results also demonstrate that the SMAD2/3 signaling pathways are required for TGF-b1-induced upregulation of CTGF. Importantly, CTGF knockdown attenuates TGF-b1-inhibited cell invasion. Furthermore, cell invasiveness is decreased by treatment with recombinant CTGF. These results provide evidence that CTGF mediates TGF-b1-inhibited human trophoblast cell invasion. (Endocrinology 158: 3620-3628, 2017) I mplantation is regulated by a complex interplay between placental trophoblasts and the endometrium. The first step in implantation involves the attachment of trophoblast cells to the surface epithelium of the endometrium. After this initial interaction, the trophoblast cells proliferate and invade the underlying stroma and vasculature to ensure a sufficient blood supply, which is required for the successful development of the fetus during pregnancy. It has been well characterized that insufficient trophoblast cell invasion and inadequate remodeling of the uterine vasculature is implicated in preeclampsia and/or fetal intrauterine growth restriction (1, 2).
I
mplantation is regulated by a complex interplay between placental trophoblasts and the endometrium. The first step in implantation involves the attachment of trophoblast cells to the surface epithelium of the endometrium. After this initial interaction, the trophoblast cells proliferate and invade the underlying stroma and vasculature to ensure a sufficient blood supply, which is required for the successful development of the fetus during pregnancy. It has been well characterized that insufficient trophoblast cell invasion and inadequate remodeling of the uterine vasculature is implicated in preeclampsia and/or fetal intrauterine growth restriction (1, 2) .
The CCN family consists of the following six members: (1) cysteine-rich protein 61 (CCN1), (2) connective tissue growth factor (CTGF, or CCN2), (3) nephroblastoma overexpressed gene (CCN3), (4) Wnt-inducible secreted protein-1 (CCN4), (5) Wnt-inducible secreted protein-2 (CCN5), and (6) Wnt-inducible secreted protein-3 (CCN6). CCN1-6 are matricellular proteins that can modulate many cellular functions in response to different environmental stimuli (3, 4) . CCN1 and CCN3 are expressed in extravillous trophoblast cells and endometrium. CCN2 is expressed in cytotrophoblast cells, syncytiotrophoblast cells, extravillous trophoblast cells, and endometrium (5) . CCN1, CCN2, and CCN3 have been shown to be involved in the regulation of implantation, although thus far, nearly nothing is known about the expression and function of CCN4, CCN5, and CCN6 in the female reproductive organs (5) . Of specific interest are previous studies showing that CCN1 and CCN3 levels are downregulated in the placenta and serum of preeclamptic patients. In contrast, CTGF messenger RNA (mRNA) levels in the placenta and CTGF serum levels from patients with severe preeclampsia or fetal growth restriction are higher than in controls (6) (7) (8) (9) . These studies suggest that CCN1, CCN2, and CCN3 dysregulation may contribute to placental diseases and that CCN family members have multifunctional roles in regulating the pathogenesis of these diseases.
Transforming growth factor-b1 (TGF-b1) has multifunctional roles in the regulation of various physiological and pathological processes (10) . TGF-b1 and its receptors, TGF-b receptor type I (TbRI) and TGF-b receptor type II, are expressed in human trophoblast cells (11) . In pigs, CTGF expression levels are highly correlated with TGF-b1 expression at the uteroplacental interface during early pregnancy (12) . This study suggests that CTGF may mediate some TGF-b1 functions during implantation. However, the function of CTGF in the regulation of trophoblast invasion remains unknown. We and other groups have shown that treatment with TGFb1 inhibits human trophoblast cell invasion (13) (14) (15) . TGF-b1 has been shown to be a strong stimulator for CTGF expression in various cell types, including cells derived from female reproductive organs (16) (17) (18) . To date, whether TGF-b1 can upregulate CTGF expression in human trophoblast cells is unclear. Additionally, if CTGF expression levels can be upregulated by TGF-b1, whether CTGF mediates TGF-b1-inhibited human trophoblast cell invasion remains unknown.
In the present study, we examined the effect of TGFb1 on CTGF expression in human trophoblast cells. Our results show that TGF-b1 treatment upregulated CTGF expression in the human trophoblast cell line HTR-8/SVneo as well as in primary human trophoblast cells. Using pharmacological inhibitor and small interfering RNA (siRNA), we demonstrated that the TGF-b receptor and activation of the SMAD2/3 signaling pathways are required for TGF-b1-induced upregulation of CTGF expression. Moreover, CTGF knockdown attenuated TGF-b1-inhibited trophoblast cell invasion. Furthermore, basal cell invasion levels were decreased after treatment with recombinant human CTGF. These results provide evidence that CTGF plays important roles in regulating trophoblast cell invasion.
Materials and Methods

Cell culture
The human trophoblast cell line HTR-8/SVneo was provided by Dr. Charles Graham (Queen's University, Kingston, ON, Canada). HTR-8/Svneo is an SV40 large T antigen immortalized first trimester short-lived extravillous trophoblast cell line (19) . Cells were grown in a 1:1 (volume/volume) mixture of DMEM/F12 medium (Gibco/Life Technologies, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT). Cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 in air.
Primary trophoblast cell culture
Human trophoblast cells were isolated from first trimester placental tissue explants as previously described (20) . Briefly, chorionic villi were washed with cold medium and finely minced. Fragments of the chorionic villi were allowed to adhere for 2 to 3 days, after which any nonadherent material was removed. These tissue explants were further cultured for 10 to 14 days, during which the culture medium was changed every 2 days. Trophoblast cells were separated from the villous explants by a brief trypsin digestion.
Antibodies and reagents
The monoclonal anti-SMAD2, anti-SMAD3, and polyclonal anti-TbRI and anti-SMAD4 antibodies were obtained from Cell Signaling Technology (Danvers, MA). Polyclonal anti-CTGF and monoclonal anti-a-tubulin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) ( Table 1) . Horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit immunoglobulin G were obtained from Bio-Rad Laboratories (Hercules, CA). Horseradish peroxidase-conjugated donkey anti-goat immunoglobulin G was obtained from Santa Cruz Biotechnology. The recombinant human TGF-b1 was obtained from R&D Systems (Minneapolis, MN). The recombinant human CTGF was obtained from Peprotech (Rocky Hill, NJ). SB431542 was obtained from Sigma-Aldrich (Oakville, ON, Canada).
siRNA transfection
To knock down endogenous TbRI, SMAD2, SMAD3, SMAD4, and CTGF, cells were transfected with 50 nM ON-TARGETplus SMARTpool siRNA that targets specific genes (Dharmacon, Lafayette, CO) and using Lipofectamine RNAiMAX (Invitrogen/Life Technologies, Burlington, ON, Canada). The siCONTROL nontargeting pool siRNA (Dharmacon) was used as the transfection control. The knockdown efficiency was examined using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) or western blot analysis.
Western blot analysis
Cells were lysed in cell lysis buffer (Cell Signaling Technology). Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes. After 1 hour of blocking with 5% nonfat dry milk in Tris-buffered saline, the membranes were incubated overnight at 4°C with primary antibodies, which were diluted in 5% nonfat dry milk in Tris-buffered saline. Following primary antibody incubation, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected using an enhanced chemiluminescent substrate and X-ray film. The intensities of the bands were quantified by densitometric analysis using Scion Image software (Scion, Frederick, MD). The membranes were stripped with stripping buffer [(62.5 mM Tris, 10 mM dithiothreitol, 2% sodium dodecyl sulfate (pH 6.7)] at 50°C for 30 minutes and reprobed with a-tubulin as a loading control.
RT-qPCR
Total RNA was extracted using TRIzol reagent (Invitrogen/ Life Technologies) according to the manufacturer's instructions. Reverse transcription was performed with 3 mg of RNA, random primers, and Moloney murine leukemia virus RT (Promega, Madison, WI). The following primers used for SYBR Green RT-qPCR (1) (antisense). RT-qPCR was performed using an Applied Biosystems 7300 Real-Time PCR System equipped with a 96-well optical reaction plate. The specificity of each assay was validated by melting curve analysis and by agarose gel electrophoresis of the PCR products. All of the RT-qPCR experiments were run in triplicate, and a mean value was used to determine the mRNA levels. Water and mRNA without reverse transcription were used as negative controls. Relative quantification of the mRNA levels was performed using the comparative cycle threshold (DDCt) method with GAPDH as the reference gene and using the equation 2 -DDCt . In RT-qPCR, to make the DDCt calculation valid, the amplification efficiencies of the target and reference must be approximately equal. A sensitive method for assessing whether two amplicons have the same efficiency is to look at how the DCt value varies with the template dilution (21) . Based on the Applied Biosystems Real-Time PCR Systems Guideline (part no. 4348358), the absolute value of the slope of the log input amount vs the DCt should be ,0.1. All primers used in this study passed the validation test.
Invasion assay
Transwell cell culture inserts (8-mm pore size, 24 wells, BD Biosciences) were coated with 1 mg/mL growth factor-reduced Matrigel (BD Biosciences, Mississauga, ON, Canada). Cells (1 3 10 5 cells per insert) in DMEM/F12 medium that was supplemented with 0.1% FBS were incubated for 48 hours against a gradient of 10% FBS. Noninvading cells were removed with a cotton swab from the upper side of the membrane. Cells that penetrated the membrane were fixed with cold methanol. The cell nuclei were stained with crystal violet (0.5%, Sigma-Aldrich) for 30 minutes and subsequently washed thoroughly with tap water. Each individual experiment was performed with triplicate inserts. In each insert, five microscopic fields were photographed under an optical microscope and the cell number was counted manually. The invasion assay results were normalized with the untreated control and expressed as mean 6 standard error of the mean (SEM) of at least three independent experiments.
Statistical analysis
The results are presented as the mean 6 SEM of at least three independent experiments. For experiments involving only two groups, the data were analyzed by Excel with a two-sample t test assuming unequal variances. Multiple group comparisons were analyzed by one-way analysis of variance followed by Tukey multiple comparison tests using Prism software (GraphPad Software, San Diego, CA). A significant difference was defined as P , 0.05.
Results
TGF-b1 upregulates CTGF expression in human trophoblast cells
Our previous study has shown that treatment of human trophoblast cell line HTR-8/SVneo with 5 ng/mL TGF-b1 significantly decreased cell invasion (13) . Therefore, 5 ng/mL TGF-b1 was used in the ensuing experiments. To examine the effects of TGF-b1 on CTGF expression in human trophoblast cells, HTR-8/ SVneo cells were treated with 5 ng/mL recombinant human TGF-b1 for different time periods. The RT-qPCR results showed that 1 hour of TGF-b1 treatment significantly upregulated CTGF mRNA levels and that the stimulatory effects persisted at comparable levels for 24 hours of treatment (Fig. 1A) . Western blot analysis showed that CTGF protein levels were upregulated in HTR-8/SVneo cells by treatment with TGF-b1 (Fig. 1B) . It is well characterized that CTGF can be glycosylated, which results in different protein sizes (22) . Typically, dependent on the tissue, cell type, and treatment, multiple bands at ;37 kDa can be detected by the western blot (17, (23) (24) (25) . Furthermore, TGF-b1 treatment also upregulated CTGF protein levels in primary human trophoblast cells that were isolated from three different first trimester placental tissue explants (Fig. 1C) .
TGF-b receptor is required for TGFb1-induced upregulation of CTGF
It has been well characterized that TGF-b1 initiates its signals by binding to the transmembrane type II receptor, which consequently recruits and phosphorylates the type I receptor (TbRI) and leads to the activation of downstream intracellular signaling (26) . To examine the requirement of the TGF-b receptor in TGF-b1-induced CTGF upregulation, a potent and specific TbRI inhibitor, SB431542, was used to block the function of TbRI (27) . As shown in Fig. 2A , pretreatment with SB431542 for 1 hours did not affect basal CTGF protein levels, whereas TGF-b1-upregulated CTGF protein levels were abolished by SB431542 pretreatment. Similar results were observed in the primary human trophoblast cells (Fig. 2B) . We next used specific siRNA to knock down endogenous TbRI expression to avoid the possible off-target effects of the pharmacological inhibitor. As shown in Fig. 2C , RT-qPCR analysis confirmed significantly reduced TbRI mRNA levels in the HTR-8/SVneo cells transfected with TbRI siRNA. Importantly, TGF-b1-upregulated CTGF mRNA levels were abolished by TbRI knockdown. Similarly, western blot analysis showed that TbRI siRNA significantly downregulated TbRI protein levels in HTR-8/SVneo cells. TbRI knockdown also abolished the stimulatory effects of TGF-b1 on CTGF protein levels (Fig. 2D ).
SMAD2/3 signaling pathways are involved in TGF-b1-induced upregulation of CTGF SMAD2 and SMAD3 are the major intracellular signaling pathways that mediate TGF-b1-regulated cellular functions. Upon TGF-b1 treatment, activated TbRI can phosphorylate SMAD2 or SMAD3, which subsequently bind with the common SMAD, SMAD4. The SMAD complexes then translocate into the nucleus where they mediate TGF-b1-regulated gene expression by binding to the SMAD-specific binding elements in the promoter region (28) . To examine whether the SMAD signaling pathways are involved in the TGFb1-induced upregulation of CTGF expression in human trophoblast cells, we first knocked down SMAD4 expression to block SMAD signaling pathway activation. As shown in Fig. 3A , SMAD4 knockdown abolished TGF-b1-induced upregulation of CTGF mRNA levels. Western blot analysis showed that SMAD4 siRNA significantly downregulated SMAD4 protein levels. Additionally, the upregulation of CTGF protein levels induced by TGF-b1 treatment was also abolished by SMAD4 knockdown (Fig. 3B) . These results indicate that the SMAD signaling pathways are required for TGF-b1-induced upregulation of CTGF expression in human trophoblast cells. Interestingly, SMAD2 and SMAD3 have been shown to function redundantly in the ovary (29) . To further examine whether the same is true in trophoblast cells, we used specific siRNA to knockdown either SMAD2 or SMAD3 individually. As shown in Fig. 4A and 4B, knockdown of either SMAD2 or SMAD3 partially attenuated the TGF-b1-induced upregulation of CTGF mRNA levels. Similarly, western blot analysis showed that the TGF-b1-upregulated CTGF protein levels were partially attenuated by SMAD2 or SMAD3 knockdown (Fig. 4C and 4D ).
CTGF mediates TGF-b1-inhibited human trophoblast cell invasion
Our previous study showed that TGF-b1 inhibits HTR-8/SVneo cell invasion (13) . To examine whether CTGF mediates TGF-b-inhibited human trophoblast cell invasion, we used siRNA to knock down CTGF expression. As shown in Fig. 5A , CTGF siRNA not only downregulated the CTGF basal protein levels but also abolished TGF-b1-induced upregulation of the CTGF protein levels. Consistent with our previous study, treatment with TGF-b1 significantly inhibited the invasiveness of HTR-8/SVneo cells. Interestingly, CTGF knockdown attenuated TGF-b1-inhibited cell invasion (Fig. 5B) . Moreover, treatment of HTR-8/SVneo cells with 50 or 100 ng/mL recombinant CTGF inhibited cell invasiveness (Fig. 5C ). To confirm that the inhibitory effects of CTGF on cell invasiveness were not due to differences in cell growth, the effects of recombinant CTGF on the cell proliferation were examined by trypan blue exclusion assay. As shown in Fig. 5D , treatment with 100 ng/mL recombinant CTGF for 48 hours did not affect HTR-8/ SVneo cell number. These results indicate that TGF-b1-induced CTGF acts as a suppressor of human trophoblast cell invasion.
Discussion
CTGF is expressed in trophoblast cells, although its function in the regulation of implantation remains largely unknown (5). It has been shown that CTGF knockout mice die directly after birth due to respiratory failure without placental defects, which indicates that CTGF expression is not required for normal placenta development (30) . In preeclampsia, a placental disease that is caused by inadequate trophoblast cell invasion and spiral artery remodeling, placental CTGF expression is significantly upregulated compared with healthy controls (6, 9) . These studies suggest that CTGF may play important roles in regulating trophoblast cell invasion and spiral artery remodeling. In the present study, we showed that treatment of HTR-8/SVneo cells with 50 ng/mL recombinant CTGF inhibited cell invasiveness. Our results reveal that CTGF acts as a trophoblast cell invasion suppressor, which may explain the upregulation of CTGF expression in the preeclamptic placenta. Interestingly, a previous study has shown that treatment of HTR-8/SVneo cells with 1 mg/mL recombinant CTGF increases cell adhesion to collagen IV and promotes the formation of capillary-like networks (31) . This study indicates that CTGF is required for spiral artery remodeling. Importantly, note that serum CTGF levels are ;20 ng/mL (32, 33) . Therefore, in that study, 1 mg/mL recombinant CTGF promoted HTR-8/SVneo cell adhesion and capillary-like network formation, which is not under normal physiological conditions. However, given the broad cellular range of CTGF functions, the exact roles of CTGF in placental diseases require future investigation. Elevated TGF-b1 levels in serum and placental tissues have been identified in pregnant women with preeclampsia compared with normotensive pregnant women (34) (35) (36) . We and other groups have demonstrated that TGF-b1 can inhibit trophoblast cell invasion by regulating vascular endothelial cadherin expression and protease activity (14, 15, 37, 38) . In the present study, we showed for the first time that TGFb1 upregulated CTGF expression and demonstrated that CTGF mediated TGF-b1-inhibited cell invasiveness in human trophoblast cells. These findings demonstrate a novel mechanism for the effects of TGF-b1 on trophoblast invasion. The molecular mechanisms involved in regulating CTGF expression have been investigated. To date, it is known that various signaling pathways mediate CTGF expression in response to different growth factors, cytokines, or hormone stimulation (16) . TGF-b1 has been identified as the most profound molecule that can upregulate CTGF expression. A binding site for SMAD, the major downstream effector of TGF-b1, has been identified in the CTGF promoter (39) . Interestingly, in mouse fibroblast cells and rat nucleus pulposus cells, TGFb1-induced CTGF expression is dependent on SMAD3 and SMAD4 but not SMAD2 (40, 41) . Neither SMAD2 nor SMAD3 is required for TGF-b1-induced CTGF upregulation in rat hepatic progenitor cells (42) . In human granulosa cells, both SMAD2 and SMAD3 are involved in TGF-b1-upregulated CTGF expression (17) . Taken together, these studies indicate that the requirement of the SMAD2 or SMAD3 signaling pathway for the TGF-b1-induced upregulation of CTGF is cell type-dependent. In the present study, our siRNA knockdown experiments revealed that both SMAD2 and SMAD3 are involved in TGF-b1-upregulated CTGF expression in human trophoblast cells. Notably, the protein kinase C and mitogen-activated protein kinase signaling pathways have also been reported to be involved in TGF-b1-induced upregulation of CTGF in other cell types (39) . However, whether the same is true in human trophoblast cells remains unknown and warrants further investigation.
Few studies have shown that CTGF can regulate cancer cell migration and invasion in a cell typedependent manner. CTGF overexpression stimulates breast cancer cell migration (43) . The invasion ability of colorectal cancer cell lines is inversely related to CTGF expression levels (44) . However, the underlying molecular mechanisms that mediate CTGF-regulated cell migration or invasion remain unclear. To the best of our knowledge, the effect of CTGF on cell migration or invasion in normal cell types has not yet been explored. Our results demonstrated that treatment with recombinant CTGF inhibited human trophoblast cell invasion. CTGF can modulate the activation of many signaling pathways by binding to various growth factors and membrane receptors. Therefore, CTGF has been shown to regulate a broad range of cellular functions (5, 39, 45, 46) . However, the underlying molecular mechanism that mediates CTGFregulated human trophoblast cell invasion is unknown, and investigation of this question will be of great interest in the future.
In summary, we demonstrated that TGF-b1 upregulates CTGF expression in human trophoblast cells. We show that both SMAD2 and SMAD3 are involved in TGF-b1-induced CTGF expression. Our results further demonstrate that CTGF is required for TGF-b1-inhibited human trophoblast cell invasion. CTGF knockdown attenuates TGF-b1-inhibited human trophoblast cell invasion. Furthermore, we reveal that CTGF acts as an invasion suppressor in human trophoblast cells. These results not only provide important insights into the molecular mechanisms mediating TGFb1-inhibited human trophoblast cell invasion but also increase the understanding of the physiological and pathological roles of CTGF in the placenta. (10, 50 , and 100 ng/mL), and cell invasion was examined by Matrigel invasion assay. (D) HTR-8/SVneo cells were treated with 100 ng/mL CTGF every 24 hours for 48 hours, and the cell number was examined by trypan blue exclusion assay. The results are expressed as the mean 6 SEM of at least three independent experiments. Values without a common letter were significantly different (P , 0.05). Ctrl, control.
